急性早幼粒细胞白血病的治疗进展

Progress on the Treatment of Acute Promyelocytic Leukemia

急性早幼粒细胞白血病(APL)的治疗取得了新的进展。在提高疗效的基础上进一步降低治疗的不良反应是近年来主要的研究方向之一,包括诱导方案的改进和巩固治疗策略的优化。以全反式维甲酸联合化疗为基础的治疗方案用于APL患者的治疗取得了良好的预后,提高了APL的完全缓解率。根据危险度不同进行分层治疗可以提高巩固治疗的疗效,而将微小残留病监测技术与抢先治疗相结合大大减少了血液学复发风险,使APL的治疗成为个体化治疗的典范。

The treatment of acute promyelocytic leukemia（ APL） have made new progress. On the basis of improving the treatment efficacy,to further reduce the adverse reactions was the main research in recent years,including induction programs to improve and consolidate the optimal treatment strategy. The treatment program on the basis of all-trans retinoic acid plus chemotherapy was used in the treatment of APL patients and achieved a good prognosis,increased complete remission rate of APL. To carry out substratification treatment according to different risk can improve the treatment efficacy,and the combination of minimal residual disease monitoring technology and forestall treatment can significantly reduce the risk of hematological relapse,and make the treatment of APL as a model of individual treatment.